China Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

The China flu diagnostic and treatment market is valued at US$3,543.759 million in 2020. The market is estimated to grow at a CAGR of 21.52% to reach a market value of US$13,867.909 million by 2027.

The flu diagnostics and treatment market in China is growing due to the different types of flu outbreaks in China. The demand for flu diagnostics and treatment in China is increasing due to the insufficient flu vaccine supplements in the country. With the growing population, the flu is spreading even more rapidly and causing more harm. The newly emerging influenza A (H1N1) and the expansion of the flu across the nation are a big threat to its citizens.

Inadequate government initiatives

China has not included influenza vaccination in the country’s National Immunization Program (NIP) even though it is the most effective means to prevent infection. The average national vaccination coverage in China is very low amounting to only 1-2 percent during 2004-2014, and there is even a decline in the approval of vaccines for sale by the country’s National Institute for Food and Drug Control (NIFDC). This has been due to the recent scandals that happened in China related to improper vaccines among the elderly population, which is further driving the market growth of flu diagnostic and treatment in China.

The market is projected to get a boost from this as people are losing faith in the safety of domestically produced vaccines. The low coverage of flu vaccines combined with the growing geriatric population in China will further lead to the market growth of flu diagnostics and treatment in the country.

Health concerns and awareness to drive the market

Flu diagnostic and treatment demand is also increasing in China because of increased media and public coverage, increased health campaigns, and improved access to accurate data on influenza spread across the country. The rising coverage of healthcare insurance in urban and rural areas will further induce people to use more healthcare services, thereby driving the market for flu diagnostics and treatment.

The growing infrastructure in China like a better transportation system, airlines, and high-speed rail transport, is further making it easy to spread the virus on a larger scale and in a shorter time across the country. This increases the chances of new viruses being released into the environment, thus positively impacting market growth.

The China flu diagnostic and treatment market has been segmented on the basis of the type of flu, offering, age group, and end-user. The market has been classified on the basis of type A and type B based on the type of flu. By offering, the market has been segmented into diagnostics and therapeutics. The market has been segmented on the basis of the age group of 0-14 years, 15-64 years, and >=65 years. By the end-user, the segmentation has been done based on the hospital laboratory, outpatient clinic, and reference laboratory.

Key Developments

• August 2020: Changchun BCHT Biotechnology Co (BCHT) announced the launch of its newly developed flu vaccine in China. Based on the WHO's guidelines for the flu season in 2020–2021, this intranasal seasonal flu vaccine was developed based on the joint effort of BCHT and Biodiem Ltd.
• October 2020: FUJIFILM Avigan® Tablets, an anti-influenza medication, will now be available in China thanks to a partnership between Toyama Chemical Co., Ltd. and Carelink Pharmaceutical Co., Ltd. In the future, FUJIFILM Toyama Chemical hopes to deliver Avigan to the Chinese market through a Carelink application and acceptance of Avigan for imported medicine registration.

Impact of the COVID-19 pandemic on China Flu Diagnostic and Treatment Market

The outbreak of the COVID-19 pandemic initially began in Wuhan, China in 2019, and then spread to major parts of the world. The pandemic resulted in the implementation of strict lockdown and social distancing regulations since China was among the worst-hit regions in the world. Additionally, the region was also affected by an increase in influenza cases during that time. This led to significant developments in the diagnosis and treatment of flu and related illnesses since the COVID-19 virus was also a type of flu. Hence, the market demand for flu diagnosis and treatment in the region increased significantly.

China Flu Diagnostic and Treatment Market Scope:

Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory